CYP2C19 Gene Profiling as a Tool for Personalized Stress Ulcer Prophylaxis With Proton Pump Inhibitors in Critically Ill Patients-Recommendations Proposal

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

BOŘILOVÁ LINHARTOVÁ Petra ZENDULKA Ondřej JANOSEK Jaroslav MLČŮCHOVÁ Natálie CVANOVÁ Michaela DANĚK Zdeněk KROUPA Radek BARTOŠOVÁ Ladislava LIPOVÝ Břetislav

Year of publication 2022
Type Article in Periodical
Magazine / Source Frontiers in Medicine
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.frontiersin.org/articles/10.3389/fmed.2022.854280/full
Doi http://dx.doi.org/10.3389/fmed.2022.854280
Keywords critical care; personalized therapy; stress ulcer prophylaxis; proton pump inhibitors; pharmacogenetics; gene polymorphism; poor metabolizer; ultra-rapid metabolizer
Attached files
Description To this date, there are no recommendations for personalized stress ulcer prophylaxis (SUP) in critical care that would take the patient's individual genetic predispositions into account. Of drugs used for this purpose, proton pump inhibitors (PPIs) are the first-choice drugs in intensive care unit patients. The degradation of proton pump inhibitors is mediated by cytochrome P450 (CYP) enzymes; in particular, CYP2C19 and, to a lesser extent, CYP3A4 are involved. Expression and metabolic activity of, namely in, CYP2C19 is significantly affected by single nucleotide polymorphisms, the drug metabolization rate varies greatly from ultrarapid to poor and likely influences the optimal dosage. As these CYP2C19 predictive phenotypes via CYP2C19 haplogenotypes (rs12248560/rs4244285) can be relatively easily determined using the current standard equipment of hospital laboratories, we prepared a set of recommendations for personalized PPI-based stress ulcer prophylaxis taking into account the patient's CYP2C19 predictive phenotype determined in this way. These recommendations are valid, in particular, for European, American and African populations, because these populations have the high representations of the CYP2C19*17 allele associated with the overexpression of the CYP2C19 gene and ultrarapid degradation of PPIs. We propose the CYP2C19 gene profiling as a tool for personalized SUP with PPI in critically ill patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info